The biopharmaceutical company Orexigen Therapeutics (NASDAQ:OREX) has recently developed and launched its new drug to treat obesity. Obesity is becoming major problem now-a-days especially for the younger generation and the older people. Rather than relying on exercise and natural workouts, people are starting to develop the trend of using drugs to treat such problems. This is however great news for the big pharmaceutical companies like Orexigen Therapeutics (NASDAQ:OREX) itself. The company has recently made huge profits with its obesity treating drugs. The company’s share increased by 43% during November alone and has announced better than expected quarterly results. Up till now, Orexigen (NASDAQ:OREX) has only been approved in U.S. and is expected to make its way into Europe soon. The company however, is enjoying a competitor free business currently and is the only company to produce such a drug that treats obesity.
The company currently is making its efforts to get into Europe by approving its drug and is discussing any possible drug related issues with European Union regulators. The EU problems are regarding the human use of the drug’s EU’s version. The company also appears to be resolving its drugs related issues with the Food and drug Administration advisory panel. However, the investors are already excited about the company’s movement into European market and expect to gain huge amount of profits probably even better than United States. From its Contrave licensing partner, Takeda, Orexigen (NASDAQ:OREX) gained a total of $30millions in the third quarter. The company did well as compared to the expectations of Wall Street.
The differentiating element in Orexigen Therapeutics (NASDAQ:OREX) research is its Light Study. It says that approximately 8,900-person cardiovascular outcomes studies show that in any mean time analysis, Contrave seemed to be leading to no adverse harmful events than the current standard of care. This long-term and broad-scope research study could place the Contrave way ahead of the likes of Belviq and Qsymia from its class, because of the favorable safety characteristics.
However, the investors should still remember that they in the past had also very high hopes for Belviq and Qsymia when they got approved by FDA. Until Contrave can get any support from insurer or physician support, and make customers excited about the drug, it could be just another regular slow start drug. Contrave seems to be the only potential filled drug among all the three which were approved by control management. The European health care organizations seem to be worried about the drug’s potential side effects, however given its warm reception in U.S. and no potential reported side effects has placed Contrave at a game changing position for the company. Orexigen Therapeutics (NASDAQ:OREX) , according to the experts can do better but however given the standard unapproved conditions in Europe, the investors shouldn’t attach much hopes with the company’s stock in the near future.